Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery

被引:2
作者
Xiong, Anning [1 ]
Li, Changhui [1 ]
Xu, Jianlin [1 ]
Yang, Xiaohua [1 ]
Nie, Wei [1 ]
Zhong, Hua [1 ]
Chu, Tianqing [1 ]
Zhang, Wei [1 ]
Zhong, Runbo [1 ]
Pan, Feng [1 ]
Shen, Yinchen [1 ]
Lou, Yuqing [1 ]
Zhang, Bo [1 ]
Han, Baohui [1 ]
Zhang, Xueyan [1 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, 241 Huaihai West Rd, Shanghai 200030, Peoples R China
关键词
Histologic subtype; Distant metastasis; Non-Small cell lung cancer; RESPIRATORY SOCIETY CLASSIFICATION; INTERNATIONAL-ASSOCIATION; CANCER; IMPACT; SURVIVAL; FEATURES; DISEASE; PROGNOSIS; RISK;
D O I
10.1016/j.lungcan.2021.02.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study aimed to explore the prognostic significance of solid pattern for bone metastases (BM) in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma patients after surgery. A total of 237 stage I-III lung adenocarcinoma patients with EGFR mutation were analyzed after procedure. The patients were divided into four groups: the solid-present patients with BM, the solid-absent patients with BM, the solid-present patients without BM and the solid-absent patients without BM. The bone disease-free survival (bDFS), systemic disease-free survival (DFS) and overall survival (OS) were assessed. The results revealed that the patients with solid pattern had shorter DFS (15 months vs. 19 months; P < 0.001) and OS (47 months vs. 77 months; P = 0.001). Moreover, bDFS of solid-present patients was significantly shorter than solid-absent patients (27 months vs. 14 months; P < 0.001). In addition, patients with solid component had worsened bDFS, no matter with BM as first-site development (12.5 months vs. 16.5 months; P = 0.016) or nonfirst-site development (16.5 months vs. 45.5 months; P < 0.001). These findings suggested that solid pattern predicted worse DFS and OS and also showed shortened interval between surgery and BM.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 23 条
[1]   Clinical features of metastatic bone disease and risk of skeletal morbidity [J].
Coleman, Robert E. .
CLINICAL CANCER RESEARCH, 2006, 12 (20) :6243S-6249S
[2]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386
[3]   Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis [J].
Fujimoto, Daichi ;
Ueda, Hiroyuki ;
Shimizu, Ryoko ;
Kato, Ryoji ;
Otoshi, Takehiro ;
Kawamura, Takahisa ;
Tamai, Koji ;
Shibata, Yumi ;
Matsumoto, Takeshi ;
Nagata, Kazuma ;
Otsuka, Kyoko ;
Nakagawa, Atsushi ;
Otsuka, Kojiro ;
Katakami, Nobuyuki ;
Tomii, Keisuke .
CLINICAL & EXPERIMENTAL METASTASIS, 2014, 31 (05) :543-551
[4]   Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis [J].
Gao, Dingcheng ;
Nolan, Daniel J. ;
Mellick, Albert S. ;
Bambino, Kathryn ;
McDonnell, Kevin ;
Mittal, Vivek .
SCIENCE, 2008, 319 (5860) :195-198
[5]   Skeletal Disease Contributes Substantially to Morbidity and Mortality in Patients with Lung Cancer [J].
Hirsh, Vera .
CLINICAL LUNG CANCER, 2009, 10 (04) :223-229
[6]   Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival [J].
Hung, Jung-Jyh ;
Yeh, Yi-Chen ;
Jeng, Wen-Juei ;
Wu, Kou-Juey ;
Huang, Biing-Shiun ;
Wu, Yu-Chung ;
Chou, Teh-Ying ;
Hsu, Wen-Hu .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) :2357-U244
[7]   The incidence and clinical impact of bone metastases in non-small cell lung cancer [J].
Kuchuk, Michael ;
Kuchuk, Iryna ;
Sabri, Elham ;
Hutton, Brian ;
Clemons, Mark ;
Wheatley-Price, Paul .
LUNG CANCER, 2015, 89 (02) :197-202
[8]   Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials [J].
LeVasseur, Nathalie ;
Clemons, Mark ;
Hutton, Brian ;
Shorr, Risa ;
Jacobs, Carmel .
CANCER TREATMENT REVIEWS, 2016, 50 :183-193
[9]   Metastatic sites and survival in lung cancer [J].
Riihimaeki, M. ;
Hemminki, A. ;
Fallah, M. ;
Thomsen, H. ;
Sundquist, K. ;
Sundquist, J. ;
Hemminki, K. .
LUNG CANCER, 2014, 86 (01) :78-84
[10]   Cytologic Subtyping of Lung Adenocarcinoma by Using the Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) Adenocarcinoma Classification [J].
Rodriguez, Erika F. ;
Monaco, Sara E. ;
Dacic, Sanja .
CANCER CYTOPATHOLOGY, 2013, 121 (11) :629-637